CancerCare and Craig Sager, AML Patient and Two Time Bone Marrow Transplant Recipient, Driving Much Needed Awareness to AML Throughout the Month of June to Benefit all Patients With AML. Patient Focused Educational Event on June 17, 2016 to Include Actinium Advisory Board Member Dr. John Pagel to Discuss Bone Marrow Transplant for Patients With AML

New York, NY -- (SBWIRE) -- 06/02/2016 -- Actinium Pharmaceuticals, Inc.("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of patients with advanced cancers, applauds CancerCare for their work to make June 2016 the first ever Acute Myeloid Leukemia (AML) Awareness Month. Throughout AML Awareness Month, CancerCare will feature educational information for the AML community that can be accessed via CancerCare's website (http://www.cancercare.org/amlaware) as well as social media efforts to raise awareness for AML.

Also, on June 17, 2016 at 1:30 pm ET, CancerCare will host a free virtual education program for patients with AML, their families and caregivers. One topic of the education program titled, "Transplantation as a Treatment Option for AML" will be led by Dr. John Pagel, MD, PhD, DSc, Chief, Hematologic Malignancies Program, Swedish Cancer Institute. Actinium's lead program, Iomab-B, is intended, upon approval, to prepare relapsed or refractory patients with AML over the age of 55 for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Iomab-B is expected to begin a pivotal Phase 3 trial in mid-2016.

Sandesh Seth, Actinium's Executive Chairman stated, "We are thankful to have the opportunity to support AML Awareness Month and thank CancerCare for their hard work and effort in putting this together. AML is clearly an underserved disease as evidenced by the fact that no new therapies have been approved for AML patients in 40 years. With June now being AML Awareness Month we at Actinium are hopeful that this will lead to increased awareness of AML and that in turn will lead to increased funding and research to improve outcomes for patients. We ask everyone to do their part and participate in AML Awareness Month to increase drive awareness for patients, families and caregivers that make up the AML community.

About CancerCare ®
Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. CancerCare's comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by oncology social workers and world-leading cancer experts. Headquartered in New York, NY, CancerCare maintains three additional locations in Norwalk, CT, Ridgewood, NJ and Syosset, NY.

To learn more, visit http://www.cancercare.org or call 800-813-HOPE (4673).

About Iomab-B
Iomab-B is about to begin the pivotal, Phase 3 SIERRA trial and is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct the single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Selection of leading radiopharmaceutical manufacturer and distributor signifies additional progress to pivotal Phase 3 SIERRA trial launch

New York, NY -- (SBWIRE) -- 04/14/2016 -- Actinium Pharmaceuticals, Inc.("Actinium" or the "Company"), a bio-pharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has entered into an agreement with Zevacor Pharma, Inc. (formerly IBA Molecular North America, Inc.) for the clinical production and supply of Iomab-B for the upcoming pivotal Phase 3 SIERRA trial. Pursuant to the agreement, Zevacor Pharma, Inc. will perform the Good Manufacturing Practices (GMP) manufacturing, testing, releasing and distribution of Iomab-B for Actinium's pivotal Phase 3 SIERRA trial. Iomab-B is a radioimmunotherapy intended to be an induction and conditioning agent prior to a bone marrow transplant for Acute Myeloid Leukemia (AML) patients over the age of 55. Actinium's Iomab-B has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the pivotal Phase 3 SIERRA trial is expected to enroll 150 patients.

Kaushik J. Dave, Ph.D., MBA, Actinium's Chief Executive Officer said, "We are delighted to have Zevaor as our manufacturing and supply partner for Iomab-b and the Phase 3 SIERRA trial. Zevacor is a leading radio-pharmaceutical company and it was apparent to us that they possess the knowledge, experience and capabilities to execute on our behalf, which led us to their selection. We look forward to working with the Zevacor team on the execution of the SIERRA trial."

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals stated, "The selection of Zevacor marks an important milestone for our Iomab-B program and complements the capabilities of our clinical development team and contract research organization, Medpace. Actinium and are partners are intensely focused on the pivotal Phase 3 SIERRA trial and we are confident in our capabilities. We look forward to initiating the SIERRA trial and enrolling patients that can benefit from Iomab-B and a bone marrow transplant. "

About Zevacor Pharma, Inc.
Zevacor Pharma, Inc. (formerly IBA Molecular North America, Inc.) is a leading developer, manufacturer, and distributor of radio-pharmaceutical products and educational services used in nuclear medicine and molecular imaging in the United States. Zevacor has a unique product portfolio of tracers that are aimed at improving patient care through the better diagnosis and treatment of disease. Zevacor also provides investigative and custom radio-labeling services to pharmaceutical, biotech, and research institutions nationwide helping them develop the next generation of molecular imaging and therapeutic products. Zevacor Pharma, Inc. is an affiliate of Zevacor Molecular, a PET and SPECT radio-pharmaceutical firm based in Noblesville, Indiana and both are a subsidiary of Illinois Health and Science (IHS), a non-profit healthcare system that specializes in enhancing patient care through strategic investments in healthcare-related opportunities. The Zevacor family takes pride in role helping fulfill IHS's mission to enhance longevity and the quality of human life through improved patient care and outcomes. For more information, please visit http://www.zevacor.com.

About the SIERRA trial
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study, if it is successful. The population in this two arm, randomized, controlled, multi-center trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in almost 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based bio-pharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radio-pharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radio-pharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multi-center Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multi-center trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

• SIERRA - Study of Iomab-B in Elderly Relapsed or Refractory AML • Webinar scheduled for Tuesday, April 26, 2016 at 8:30 am ET

New York, NY -- (SBWIRE) -- 04/11/2016 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will host a webinar to discuss the SIERRA trial, the Company's upcoming pivotal Phase 3 clinical trial for Iomab-B. The webinar will provide an overview of the use of hematopoietic stem cell transplant (HSCT), known as a bone marrow transplant (BMT) in relapsed or refractory Acute Myeloid Leukemia (AML) patients over the age of 55, an introduction to the SIERRA trial and anticipated timelines and milestones for the trial. Participant information for the webinar is as follows:

Date: April 26, 2016
Time: 8:30 am EST
Link: https://event.webcasts.com/starthere.jsp?ei=1098822

Speakers:
- Sandesh Seth, Executive Chairman, Actinium Pharmaceuticals
- Frank Smith, M.D., FAAP, FACP, Vice President, Medical Affairs, Medpace
- Felix Garzon, M.D., Ph.D., Senior Vice President, Head of Clinical Development, Actinium Pharmaceuticals

Felix Garzon, M.D., Ph.D., Actinium's Head of Clinical Development, Senior Vice President said, "Since FDA's acceptance of the IND for Iomab-B in December, we have successfully completed many of the steps necessary to commence the SIERRA trial including expanding our clinical operations team, securing Medpace as our CRO partner and actively engaging with major transplant centers as potential clinical trial sites. I am excited by our progress to date and am confident in our ability to successfully complete this trial efficiently and effectively."

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals stated, "The upcoming SIERRA trial is the result of years of hard work from the team at Actinium and from our collaboration with the Fred Hutchinson Cancer Research Center, and its clinicians and researchers. The SIERRA trial represents a landmark event for the world of bone marrow transplant in elderly AML patients and we are intensely committed to the execution of this trial to meet the needs of this underserved patient population who have dismal therapeutic options. We look forward to hosting this webinar as an informational event for patients, physicians, investors and all others that are interested in Iomab-B and the SIERRA trial."

About the SIERRA trial
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study, if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in almost 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Dr. Franklin O. Smith, III, MD
Dr. Frank Smith received his MD degree from the University of South Carolina School of Medicine and completed post-doctoral training in pediatrics at the University of Florida and fellowship training in pediatric hematology/oncology at the University of Washington and the Fred Hutchinson Cancer Research Center. Prior to joining Medpace, Dr. Smith was instrumental in helping build two prestigious stem cell transplant programs at both the University of Cincinnati Cancer Institute and at Riley Hospital for Children at Indiana University. He also was the Director, Division of Hematology/Oncology at Cincinnati Children's Hospital Medical Center and Vice-Chair of the Children's Oncology Group. He is an adjunct Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine, and has had over 150 scientific manuscripts published in medical and scientific journals. Dr. Smith is active with various national and international committees and societies in the field of research and clinical care, including serving on the local and national boards of the Leukemia and Lymphoma Society, Chair of the Board of Managers for the Foundation for the Accreditation of Cellular Therapy (FACT) Consulting Services, faculty for the ASCO/AACR Clinical Cancer Research Workshop and as a member of the NCI's Central Institutional Review Board. Dr. Smith has also served on ad-hoc committees for the FDA including Special Emphasis Panels for Orphan Products Development.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company Continues to Build on Strong Year-End Momentum Preparing for Phase 3 and Phase 2 Trials that are Expected to Transform Company Profile

New York, NY -- (SBWIRE) -- 03/15/2016 -- Actinium Pharmaceuticals, Inc.("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers provided investors with an update on its business progress following the filing of its 2015 10-K.

Recent Highlights
- Received clearance from the FDA for its Iomab-B IND filing in mid-December 2015 enabling the Company to proceed with a pivotal Phase 3 clinical trial
- Selected Medpace, Inc. as its Contract Research Organization (CRO) for the pivotal Phase 3 Iomab-B clinical trial
- Filed for Orphan Drug Designation for Iomab-B in November 2015
- Significant company presence focused on physician interaction at the February 2016 annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and American Society of Blood and Marrow Transplantation (ASBMT), referred to as the BMT Tandem Meetings.
- On track to start Phase 2 portion of Actimab-A trial mid-2016
- Strategically added key senior level professionals to the clinical development team including highly experienced clinical operations and product development professionals, bringing total employee count to 17 as of March 11, 2016
- Filed two provisional patent applications related to Iomab-B to bolster intellectual property portfolio
- Significantly increased capital markets activity with presentations at 5 investor oriented conferences in Q1 2016 and coverage by 2 equity research analysts in past several months

Iomab-B: Dedication to execution of single, pivotal Phase 3 trial

In the fourth quarter of 2015 Actinium filed and received clearance of the Investigational New Drug (IND) application for Iomab-B. This event signaled the elimination of a major risk factor regarding the availability of bioequivalent clinical supplies for Iomab-B. The Company is now focused on executing the single, pivotal trial for Iomab-B based on which the company believes it will be able to file a Biologics License Application with the US Food and Drug Administration. In anticipation of this trial, Actinium has added experienced staff members in clinical development, clinical operations and product development to meet the increased levels of activity. Also, the Company has engaged Medpace, Inc. as its CRO to help manage the pivotal Phase 3 Iomab-B trial. Medpace is a 2,400 person global organization and was selected due to their expertise and experience in hematology and bone marrow transplant. Actinium applied for Orphan Drug Designation for Iomab-B in Q4 2015 and is awaiting the FDA's response to its application. Finally, Actinium has initiated the process to obtain EU orphan designation for Iomab-B and has engaged a leading regulatory consulting firm to assist the Company with its efforts.

Iomab-B is a potentially revolutionary treatment option for refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. Iomab-B is intended to be an induction and conditioning agent prior to a hematopoietic stem cell transplantation (HSCT) or Bone Marrow Transplant (BMT). The pivotal Phase 3 trial size is set at 150 patients, randomized 1:1, with 75 patients per arm. The primary endpoint is durable complete remission, defined as a complete remission lasting at least 6 months, and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. In its proof of concept trial, Iomab-B results showed that it tripled the rate of survival at one year and twenty percent survived at two years. These results are generating strong support for the trial by many of the leading specialists in the field, as evidenced by strong support from Key Opinion Leaders (KOLs) that was seen at the BMT Tandem Meetings.

Actimab-A: Results from Phase 1 portion of Phase 1/2 trial presented at major medical conference

Data from the fourth and final cohort of the Phase 1 portion of the Actimab-A clinical trial, in which patients were being treated at 2.0 ?Ci/kg dose level of Actimab-A, up from 0.5, 1.0 and 1.5 ?Ci/kg per fractionated dose, were presented at the American Society of Hematology 2015 Annual Meeting along with results from previous cohorts. In total, 4 of 14 (29%) evaluable patients had an objective response with 1 complete remission (CR), 2 complete remissions with incomplete platelet count recovery (CRp) and 1 complete remission with incomplete blood count recovery (CRi) reported. Bone marrow blast reductions were seen in 8 of 11 (73%) evaluable patients. The Phase 2 portion of the trial is expected to commence by mid-2016.

Increased capital markets activity

In 2015, the Company presented at 11 investor conferences. In Q1 2016, the Company has presented or will present at a total of 5 investor conferences including:
-Biotech Showcase – January 11, 2016, San Francisco, CA
-BIO CEO & Investor Conference – February 9, 2016, New York, NY
-Cowen and Company 36th Annual Healthcare Conference – March 8, 2016, Boston, MA
-BioCentury Future Leaders in the Biotech Industry Conference – March 11, 2016, New York, NY
-28th Annual ROTH Conference – Laguna Nigel, CA, March 15, 2016

In addition to increased conference activity, the Company has attracted the attention of equity research analysts and is now covered by:
-Vernon Bernadino – FBR & Co.
-Andrew Fein – H.C. Wainwright & Co.

The Company believes that these efforts increase awareness for and raise the profile of Actinium with investors and the capital markets. Management will continue these activities with the goal of increasing shareholder value and liquidity.

Investor oriented events planned for Q2 2016
An investor oriented event will be held in Q2 2016 focused on Iomab-B and its upcoming pivotal Phase 3 trial. In addition, the Company will also host other KOL events throughout the year in order to update and educate investors about its progress. Actinium had originally anticipated holding an R&D day in Q1 2016, however, decided not to hold the event heeding the advice of its investor relations advisors. The key driver in deciding to hold a series of KOL throughout 2016 versus hosting a single R&D day was to mitigate the risk that the R&D day could be disregarded by biotech institutional investors given the uncertainty in the biotech capital markets. It is anticipated that an additional KOL day focused on Actimab-A will be held subsequent to the Iomab-B KOL day as well as other events in the second half of 2016.

Company on track to transform profile from focus on early-stage to later-stage clinical development during 2016.
Actinium's profile is expected to change significantly in 2016 as the Company transitions to a later stage clinical development enterprise upon the start of the pivotal Phase 3 Iomab-B trial and the Phase 2 Actimab-A trial. S everal milestones are anticipated for the Company in 2016 including:
- Orphan Drug Designation for Iomab-B
- Clinical trial site and IRB contracts executed with top BMT centers
- Initiation of pivotal Phase 3 Iomab-B clinical
- Filing of EU Orphan Medicine Designation applications for Actimab-A
- Progress on EU Orphan Medicine application process for Iomab-B
- Initiation of Phase 2 portion of Actimab-A Phase 1/2 clinical trial
- Interim data from Actimab-A Phase 2 clinical trial
- Enrollment updates from Iomab-B clinical trial via Data Safety Monitoring Board readouts
- KOL days focused on Iomab-B and Actimab-A, respectively
- Pipeline and strategic initiative updates

Actinium entered 2016 with a strong balance sheet with approximately $25 million cash and has built a team comprised of highly motivated and experienced professionals led by proven pharmaceutical executives. These strengths along with a dedication to improving the lives of Acute Myeloid Leukemia patients and patients suffering from other difficult to treat cancers with targeted payload immunotherapeutics will drive the Company's efforts in 2016.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company's Patent Portfolio Continues to Expand as Programs Progress

New York, NY -- (SBWIRE) -- 03/09/2016 -- Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's Iodine-131 labeled anti-CD45 antibody. This provisional patent application represents the second provisional patent application filing related to Iomab-B following the Company's June 24, 2015 filing for infusion administration of Iomab-B. A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file a subsequent patent with similar claims.

Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium Pharmaceuticals said, "This provisional patent application represents another valuable addition to our intellectual property portfolio. We remain committed to the strategic enhancement of our intellectual property portfolio in alignment with our development of targeted payload immunotherapeutics."

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, "2016 will be a transformational year for Actinium as we transition to a later stage company with the commencement of the Iomab-B Phase 3 pivotal trial and the Actimab-A Phase 2 clinical trial. The strengthening of our intellectual property portfolio is an integral aspect of Actinium's growth and today's provisional patent application demonstrates our commitment to this goal."

Actinium's broad intellectual property portfolio includes 39 issued and pending patents in the U.S. and internationally. This includes 7 issued patents in the United States, 2 pending patents in the United States and 30 issued or pending international patents. The Company's patent portfolio encompasses the use of alpha emitting isotopes attached to monoclonal antibodies, methods for manufacturing key components of its product candidates and methods for manufacturing finished product candidates for use in cancer treatment.

About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on healthiest tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha -emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Strategic additions in key areas will support later stage clinical trials for Iomab-B and Actimab-A

New York, NY -- (SBWIRE) -- 01/27/2016 -- Actinium Pharmaceuticals, Inc.("Actinium"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Rowena Choudrie, M.S. to the position of Senior Director, Pharmaceutical Product Development and Kevin Zikaras to the position of Senior Clinical Scientist. These hires will report to Kaushik J. Dave, Ph.D., MBA Chief Executive Officer and Felix Garzon, M.D., Ph.D., Senior Vice President, Head of Clinical Development, respectively.

"Actinium has strategically added to our team in recent months reflecting the progress we have made with our Iomab-B and Actimab-A programs, which will both be in later stage clinical trials this year" said Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals. "The hiring of Rowena and Kevin is a display of our ability to attract top talent and I look forward to their contributions to our goal of developing and commercializing best in class therapies for diseases with unmet needs."

Ms. Choudrie has over 20 years of pharmaceutical industry experience with roles of increasing responsibility in product development. At Actinium, Ms. Choudrie will be responsible for clinical trial material supply, drug product process scale-up to support commercial supply and final product formulation. In addition, she will support Actinium's regulatory efforts particularly in the area of Chemistry, Manufacturing and Control (CMC). Most Recently, Ms. Choudrie worked at NPS Pharmaceuticals as Senior Director, Pharmaceutical Development, Global Technical Operations where she directed formulation development, process development and clinical manufacturing while managing Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs). From 2004 until 2009, Ms. Choudrie worked at Palatin Technologies, Inc. serving as Director, Formulation Development and Manufacturing where she was responsible for clinical manufacturing and supply and served as CMC working group leader to coordinate phase 1, 2 and 3 trial activities with an array of multi-disciplinary groups within the organization. From 1990 until 2004, Ms. Choudrie worked at Schering-Plough Research Institute as a Principal Engineer and Chair of the Product Development Team. At Schering-Plough, Ms. Choudrie led process development, process improvement and formulation improvement for multiple drugs. In addition, she managed internal and external technology transfers on a global basis. Finally, she contributed to multiple New Drug Applications (NDAs) and Biologics License Applications (BLAs) that received approval by the U.S. FDA and European Medicines Agency.

Ms. Choudrie received her Bachelor of Science and Master of Science degrees in Mechanical Engineering from the New Jersey Institute of Technology.

"Rowena is a proven pharmaceutical product development professional with a track record of driving process development and scale-up, managing both clinical trial and commercial product supply and executing CMC sections for numerous regulatory filings. I welcome her to our team and am delighted to have the benefit of her product development knowledge and experience" said Kaushik J. Dave, Ph.D., Chief Executive Officer of Actinium Pharmaceuticals.

Mr. Zikaras joins Actinium from Bristol-Myers Squibb where he was a Clinical Protocol Manager in the Immuno-Oncology group since 2014. There he served as global clinical operations lead for the phase 3 registration trial for the lead asset indication in immuno-oncology and supported operations and regulatory filings for numerous immuno-oncology indications. From 2013 until 2014 he was Clinical Research Manager at Columbia University Medical Center where he managed Hematologic Malignancies clinical research including 8 FTEs. Also at Columbia, Mr. Zikaras managed multi-center and investigator initiated trials where his responsibilities included clinical trial development, budget creation and Investigational Review Board (IRB) submissions through completion. From 2011 until 2013, Mr. Zikaras was a Research Study Specialist at Memorial-Sloan Kettering Cancer Center where he was involved in 12 phase 1 – 3 clinical trials in hematologic malignancies including Actinium's Actimab-A program. Mr. Zikaras received his Bachelor of Arts degree with a major in biology from Bowdoin College and is an author on five publications.

Dr. Garzon, Actinium's Senior Vice President, Head of Clinical Development said, "Throughout his career Kevin has worked with leading researchers in the area of hematology and has developed strong skills in the areas of clinical trial management and operations. His experience in hematology clinical research and working experience with Actimab-A make him a valuable addition to the Actinium team."

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Orphan Drug Designation Could Provide Faster Regulatory Review and Financial Incentives

New York, NY -- (SBWIRE) -- 11/24/2015 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions refractory and relapsed Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). The Company has recently submitted an Investigational New Drug (IND) application for Iomab-B with the FDA and is preparing for a pivotal, Phase 3 trial.

Kaushik J. Dave, Ph.D., MBA, CEO of Actinium stated, "We are pleased to have filed an Application for Orphan Drug Designation for Iomab-B. We are confident that Iomab-B meets the criteria for Orphan Drug Designation and are eager to begin the Phase 3, pivotal trial for Iomab-B. Acute Myeloid Leukemia is the most common acute leukemia affecting adults and accounts for the largest number of annual deaths due to leukemia. Refractory and relapsed AML patients, particularly elderly patients, have very few, if any, treatment options other than a Bone Marrow Transplant. Unfortunately, many of these patients cannot tolerate the intensive chemotherapy given prior to BMT. We believe that Iomab-B will allow a greater number of AML patients to receive a BMT and could be a paradigm shift in the way AML patients are treated."

Actinium's Actimab-A, which is intended to treat newly diagnosed AML patients over the age of 60, received Orphan Drug Designation on December 1, 2014. Results from the Phase 1 portion of Actimab-A's Phase1/2 trial will be presented at the 57th American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida on December 4 – 8, 2015. Actimab-A data, including patients from the fourth and final cohort, will be presented in a poster session on December 7, 2015 at 6 pm EST.

About Orphan Drug Status
The FDA, through its Office of Orphan Products Development (OOPD), grants orphan status to drugs and biologic products that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Orphan drug designation provides a drug developer with certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication; potential tax credits on U.S. clinical trials; eligibility for orphan drug grants; and waiver of certain administrative fees.

About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company Gearing Up For Pivotal, Phase 3 Clinical Trial

New York, NY -- (SBWIRE) -- 11/19/2015 -- Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Pending the FDA's acceptance of the IND filing, Actinium will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55.

"We are excited to have submitted the Iomab-B IND application to the FDA," said Kaushik J. Dave, Ph.D., MBA, CEO of Actinium. "We focused heavily on Iomab-B in 2015 and overcame our previous manufacturing hurdles, which gave us great confidence when we met with the FDA for our pre-IND meeting. Our filing, well ahead of our year end guidance, is a great milestone for Actinium."

Sandesh Seth, Actinium's Executive Chairman commented, "This much anticipated regulatory filing is an important one that marks the first step in Actinium's transition to a later development stage biopharmaceutical company. As we prepare for the pivotal Phase 3 clinical trial for Iomab-B in 2016, we have added key members to our executive, regulatory and clinical operations teams and will continue to add selectively. This strengthening of the company will enable us to meet our goals of efficient execution of not only the Iomab-B program but also of the Actimab-A Phase 2 trial planned for early 2016, as well as other pre-clinical and clinical programs expected for next year."

About the Iomab-B Pivotal, Clinical Trial
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study, if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New Personnel Bolster Clinical and Regulatory Teams Ahead Of Planned Phase 3 and Phase 2 Trials

New York, NY -- (SBWIRE) -- 11/05/2015 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Dr. Xin Du, Ph.D., to the position of Executive Director, Regulatory Affairs and Dr. Sri Srivastava, Ph.D., PMP, to the position of Associate Director of Project Management. Dr. Srivastava will have operational responsibilities for Actinium's Actimab-A program including the planned Phase 2 trial, planning and process optimization, management of external vendors and the coordination of all clinical trial related matters. Dr. Du will be responsible for managing Actinium's regulatory submissions, CMC efforts, interacting with regulatory agencies and developing the Company's regulatory strategy as pertains to both Iomab-B, Actimab-A and all future programs. Both hires are especially timely given the planned transformation of Actinium into a later stage product development company in 2016.

"Actinium is pleased to announce the continued expansion of our team and the key hiring of Dr. Du and Dr. Srivastava," said Kaushik Dave, Ph.D., MBA, CEO of Actinium. "We are focused on progressing Iomab-B and Actimab-A in the clinic and we view Dr. Du's FDA and regulatory background as a major asset as we prepare Iomab-B for its single, Pivotal Phase 3 trial and believe Dr. Srivastava's CRO and project management background will be integral to our anticipated Phase 2 trial for Actimab-A."

"I am excited to be part of the Actinium team and to have the opportunity to work on promising products which could provide significant benefits to patients. I am glad that I could bring my regulatory and biological knowledge and experience in helping the transformation of Actinium into a later stage product development company and in bringing high quality products to patients", Dr. Du said.

Dr. Xin Du, Ph.D., is a senior regulatory professional with over 15 years of industry experience and a proven track record of product approvals, regulatory strategy and efficient regulatory submission management. Dr. Du began his career at the FDA as Staff Fellow at the Center for Biologics Evaluation and Research. At the FDA, Dr. Du focused on the regulation of drug production, particularly Chemistry, Manufacturing and Control (CMC) and reviewed IND and BLA submissions. Following the FDA, he has worked for several global biopharmaceutical companies such as Aventis (acquired by Sanofi), Wyeth (acquired by Pfizer), Novartis, Bristol Myers Squibb and NPS Pharmaceuticals (acquired by Shire) in regulatory affairs and CMC positions with increasing responsibility. Most Recently, Dr. Du was Senior Director and Global Regulatory CMC Head at NPS Pharmaceuticals, until the Company's acquisition by Shire, where he was instrumental in receiving approval for the Company's first BLA submission and in the successful launch of the Company's first product in Europe. Throughout his career, Dr. Du has been successful in preparing regulatory filings, managing interactions with regulatory agencies on a global basis and obtaining regulatory approvals for various drug products.

"I am delighted to join Actinium at such a transformational time for the Company. Actimab-A is an exciting radioimmunotherapeutic and I look forward to applying my clinical trial operations knowledge and experience to its development while working with the team as we guide Actimab-A through its planned Phase 2 trial", Dr. Srivastava said.

Dr. Sri Srivastava, Ph.D., PMP, has nearly two decades of successful project management and clinical operations experience with both large biopharmaceutical companies and as a consultant to emerging biopharmaceutical companies. His career includes tenures at Parke-Davis (now Pfizer), Purdue Pharma, Organon Pharmaceutical, Aestus Therapeutics, Janssen R&D and ClinTech Research. Dr. Srivastava spent a decade at ClinTech Research where he provided consulting services focused on clinical operations for emerging biopharmaceuticals including Aestus Therapeutics where he managed a randomized Phase 2 clinical trial. Dr. Srivastava has significant experience in clinical trial site and vendor oversight, developing study related documentation, designing clinical trial protocols, reviewing data management & monitoring plans, monitoring reports CSR. In addition, Dr. Srivastava has been invited speaker at clinical conferences to present multiple aspect of study management from virtual management and project optimization as it relates to clinical trials.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

IND Filing To Enable Initiation of Single, Pivotal Phase 3 Trial

New York, NY -- (SBWIRE) -- 10/07/2015 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that subsequent to its pre-IND (Investigative New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its Iomab-B drug candidate, the Company is finalizing the IND filing for submission to the FDA to support the start of the Phase 3 clinical study.

"We are quite pleased with the outcome of our pre-IND meeting which provided valuable feedback regarding our forthcoming IND submission for Iomab-B. We are close to finalizing our application package and remain on track to file the IND in the fourth quarter of this year, in-line with our guidance. We are optimistic that the FDA will award the filing an IND designation which will allow us to move into the critical Phase 3 stage for Iomab-B," noted Kaushik J. Dave, Chief Executive Officer of Actinium Pharmaceuticals. "We are also continuing to establish the infrastructure necessary to enable speedy Phase 3 development of Iomab-B."

Actinium expects to complete and file the IND submission in the fourth quarter of this year in-line with guidance provided. Based on the feedback received during the recent pre-IND meeting, and the completion of significant amounts of work related to manufacturing, the Company anticipates a straightforward path to IND designation. Once such designation is achieved, the Company can move Iomab-B into the Phase 3 trial.

About Iomab-B
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Felix Garzon MD, PH.D.: Record of Success Strengthens Team as Company Prepares for the Iomab-B Pivotal Trial

New York, NY -- (SBWIRE) -- 08/18/2015 -- Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Felix Garzon, MD, Ph.D. to the position of Senior Vice President, Head of Clinical Development effective August 17, 2015. Dr. Garzon brings with him 28 years of pertinent pharmaceutical and biotechnology experience in increasingly senior roles, most recently at Eisai and Bristol-Myers Squibb, having worked on both later and earlier stages of drug development.

"Felix's deep expertise in hematology and oncology drug development will strengthen the Actinium team in an important way. He brings to Actinium a rigorous track record of successful clinical development in diverse settings including leadership roles with international product teams in large and small companies and in different therapeutic indications," said Kaushik J. Dave, Ph.D., Chief Executive Officer of Actinium Pharmaceuticals. "In addition, Felix has significant clinical trial management and regulatory experience. All of these are key skills as we ramp up our preparations for the upcoming trials for Iomab-B and Actimab-A."

Dragan Cicic, MD, Chief Medical Officer of Actinium added, "Felix is a great addition to our team, whose vast experience in and focus on hematologic oncology will enable us to execute our ambitious programs in a timely and precise manner."

"I am very excited to join the Actinium organization," said Dr. Garzon. "Actinium is pursuing breakthroughs in the field in which I have more than a quarter of a century of professional experience. With two very promising products poised to enter Phase 3 and Phase 2 trials, I am thrilled to have an opportunity to maximize the development prospects for Iomab-B and Actimab-A. As we build and strengthen the clinical team to meet milestones, I look forward to adding value by generating high quality clinical data to help achieve timeline objectives."

Dr. Garzon has more than 28 years of robust international experience working in positions of increasing responsibility in the development of new oncology and hematology drugs in several successful companies in the United States and Europe. He has successfully led and managed the late development and approval of several anticancer drugs, including Halaven®, Trisenox® and Xyotax®. Other roles included Clinical Lead at a Product Creation Unit, Head of Medical Affairs and strategic development plan creation and implementation. Prior to his extensive work in oncology drug development for the pharmaceutical industry, he worked as a scientist in the research of new anti-cancer drugs for several years at the Institute of Toxicology & Chemotherapy of the German Cancer Research Centre, Heidelberg, Germany. Dr. Garzon is the author and co-author of over 80 relevant scientific publications, abstracts and presentations given at international scientific meetings.

Dr. Garzon was previously Senior Director, Oncology Product Creation Unit at Eisai, and Director, Oncology Global Clinical Research at Bristol-Myers Squibb. He also had roles at Chiron, Cell Therapeutics, Rhone-Poulenc Rorer, Pharmacia & Upjohn and Ipsen, following academic appointments and education in Germany, France and Argentina.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

FDA Meeting is Key Next Step in Development of Drug Candidate

New York, NY -- (SBWIRE) -- 07/16/2015 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a pre-IND (Investigative New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently preparing to commence the pivotal Phase 3 trial. During the early development of a new drug, manufacturers are required to apply for and obtain IND designation.

"We are optimistic that we will move through the meeting and application process successfully and obtain approval from the FDA that will allow us to move into the critical Phase 3 phase for Iomab-B," noted Kaushik J. Dave, President and Chief Executive Officer of Actinium Pharmaceuticals. "We have also begun to establish the infrastructure necessary to enable speedy Phase 3 development of Iomab-B, if and when we receive IND status."

About Iomab-B
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Oncology Experts Review Initial Patient Outcomes from Ongoing Actimab-A Phase I/II Clinical Trial

New York, NY -- (SBWIRE) -- 06/08/2015 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the presentation of poster and abstract at ASCO 2015, the 51stAnnual Meeting of American Society of Clinical Oncology, was given in Chicago on May 31. Data from the Company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients were presented by Dr. Joseph Jurcic of Columbia University Medical Center, Actinium's Clinical Advisory Board Chairman.

Among the first 12 patients treated at increasing dose levels, two Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi) and one patient achieved complete remission with incomplete platelet count recovery (CRp), for a combined overall response rate of 25% among all patients and 67% among patients treated at the highest dose level to date. Patients ranged from 68 to 87 years of age, all with high- or intermediate-risk cytogenetics; half of them had prior MDS therapy. Dose limiting toxicities were limited to one patient with prolonged myelosuppression. No extra medullary dose limiting toxicities were observed. Patients had high pre-treatment leukemia burdens of up to 88% in the bone marrow, and half had blast reductions >50% after Actimab-A treatment. The Company also recently began the fourth and last cohort (2.0 ?Ci/kg per dose) in the Phase I portion of this trial.

"These results generated significant interest and were well received by the oncology experts," said Dr. Joseph Jurcic, the presenter and lead author of the poster and abstract. "Oncologists were particularly excited to see objective responses in patients who already received best available therapy for their prior blood cancer."

Summary of the presented data can be found in the ASCO Abstract #7050 titled "Phase I trial of ?-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML)."

Dr. Jurcic is Director of the Hematologic Malignancies Section of the Hematology/Oncology Division and Professor of Clinical Medicine at Columbia University Medical Center. He is a hematologist/oncologist focusing on the treatment of acute and chronic leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, development of novel small molecule inhibitors for leukemia and molecular monitoring of minimal residual disease. He is the primary investigator for the current Actimab-A clinical trial and Clinical Advisory Board Chairman. He received his medical degree from the University of Pennsylvania and completed his fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.

About Actimab-A
Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from leading experts at the prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Medicine, Columbia University Medical Center, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. Actimab candidates are in early development for other cancers.

About Iomab-B
Iomab-B™ is being developed to prepare patients for hematopoietic stem cell transplantation (HSCT) and will enter a single, pivotal Phase 3 clinical study in relapsed/refractory AML. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM).

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Outlook for 2015 Includes Initiating Iomab-B Phase 3 Pivotal Trial and Advancing Licensing Discussions in Europe and Asia; Completion of Phase 1 Actimab-A Trial, Progression into Phase 2 to Support Global Licensing Activity

New York, NY -- (ReleaseWire) -- 03/11/2015 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided an overview of the Company's 2014 achievements and a business update for 2015. The stated achievements and highlights below demonstrate the significant progress the Company has made on key initiatives to support the advancement of the ongoing Phase 1/2 program and upcoming Phase 3 clinical development program for Actimab-A and Iomab-B, respectively.

In addition, the company continues to expand its visibility with leading bone marrow specialists; enhance its leadership team as most recently evidenced by the addition of Dr. Roland Turck, former President, Global Specialty Medicine, Bayer Healthcare as Senior Board Advisor; and is actively pursuing partnering and licensing opportunities for both products to support further clinical development across multiple indications in cancer and future commercialization.
Corporate and clinical milestones achieved during 2014 include:

Key 2014 Achievements

-Completion of Technology Transfer and Progression of Iomab™-B Towards Phase 3 Clinical Trial

-Advanced Actimab-A Phase 1/2 Program Supported by Positive Interim Clinical Data; Received Orphan Drug Designation from FDA

-Initiated Support for Third Development Program

-Uplisted to NYSE Markets and Added to the Russell® Indexes both support increased liquidity

-Fortified Company Infrastructure with Key Executive Hires

-Strengthened Balance Sheet

"We wish to thank our existing shareholders for their continued support this year." stated Kaushik J. Dave, Ph.D., President and Chief Executive Officer. "We have made significant progress in a number of areas, including the advancement of our lead development program Iomab-B which is anticipated to commence a Phase 3 trial in 2015, as well as reporting promising interim results in the ongoing Phase 1/2 trial for Actimab-A. Based on the favorable safety profile in clinical trials to date, Actimab-A has the potential to be a low intensity therapy for older AML patients. With respect to Iomab-B, the company is finalizing the manufacturing process to ensure the commercial quality as we enter the Phase 3 trial and, if approved by FDA, support the launch. Given the significant unmet medical need potentially addressed by Iomab-B for bone marrow transplant, and Actimab-A initially in newly diagnosed secondary acute myeloid leukemia patients, we remain confident in the potential value-creation the Company can derive from advancing both programs closer to commercialization and through ongoing partnering and licensing activities. The entire team remains focused on executing on value-creating milestones".

Recent Highlights:
At a company event held concurrent with the February 2015 BMT Tandem Meetings (the combined annual meetings of Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT)), leading bone marrow specialists, representing major academic cancer centers with high volumes of bone marrow transplant (BMT) patients, demonstrated significant interest in participating in the upcoming Iomab-B Phase 3 clinical trial.

The validation from these leading BMT physicians is anticipated to support the expansion of participation of leading sites and the pace of subject enrollment upon commencement of the trial.

Dragan Cicic, MD, Chief Medical Officer of Actinium commented, "Several well attended sessions including one entitled "What is the Optimal Conditioning Regimen?", led by Frederick Appelbaum, MD from the Fred Hutchinson Cancer Research Center which cited the strong historical safety and efficacy of Iomab-B, continue to increase awareness and support for our upcoming Phase 3 clinical trial from leading bone marrow transplant physicians. The growing positive reception and interest bodes well for our ability to drive participation from leading, high volume bone marrow transplant centers and drive patient recruitment."

The Board has retained Roland Turck, MD, former President, Global Specialty Medicine, Bayer Healthcare to provide strategic advice. At Bayer, Dr. Turck played a leadership role in the commercialization of the alpha-radiopharmaceutical Xofigo® whose successful launch he prepared in close collaboration with Algeta ASA which was subsequently purchased by Bayer for $2.9 Billion. Dr. Turck will provide guidance on the ongoing clinical development, pre-commercialization, and licensing activities for Iomab-B and clinical development and licensing activities for Actimab-A.

2015 Outlook:

-Commence Iomab™-B Phase 3 Clinical Trial and Seek Orphan Drug Designation

-Announce Completion and Clinical Data from Phase 1 Portion of Actimab-A, a Second Generation Product Candidate for Elderly AML

-Commence the Phase 2 portion of the Actimab-A trial

-Initiate Preclinical Studies for a Third Program

-Advance Partnering and Licensing Activity for Both Actimab-A and Iomab-B

-Expand Clinical, Regulatory and Pre-Commercialization Expertise to Accelerate Clinical Development and Licensing Activities

"In the near-term, we expect to move Actimab-A into the Phase 2 portion of the trial and more importantly, we plan to begin the Iomab-B Phase 3 trial," concluded Dr. Dave. "In addition, we will further strengthen our pipeline with the completion of labeling for the third program using our APIT platform and initiate preclinical studies to support first in man clinical trials. Furthermore, to support our near-term and longer-term objectives, the addition of Dr. Turck is an example of the Company's commitment to add experienced talent to enhance and accelerate the development, commercialization, and licensing potential of these highly differentiated clinical assets.

Longer-term, if successful, we expect to bring Iomab-B to market across multiple indications and further establish the clinical validity of Actimab-A to maximize the value of our pipeline and support our efforts to build a world-class bone marrow transplant and oncology company."

About Bone Marrow Transplant
Bone marrow transplants (BMT) are most commonly used to treat leukemia and lymphoma, conditions incurred when a blood or immune cell, respectively, becomes cancerous and proliferates. Together, these diseases account for some 50,000 to 75,000 new cases annually in the United States. BMT involves first clearing a patient's body of his or her own immune cells and then transplanting bone marrow, the source of all blood- and immune-forming cells, from a tissue-matched donor. The new cells, which are free of cancer, repopulate the patient's bone marrow and eventually give rise to a functioning set of blood and immune cells, providing a lifelong cure. BMT offers the chance of a "curative" outcome (2+ year survival), and therefore can play a central role in the treatment of AML. The impact of BMT on AML continues to increase with AML being the most common and fastest growing indication for allogeneic BMT, comprising 25% to 30% of all BMT recipients. There are currently over 100,000 BMT survivors across all indications and this number is expected to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them over age 60.

About AML
Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. It is characterized by an uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates there will be approximately 18,860 new cases of AML and approximately 10,460 deaths from AML in the U.S. in 2014. Patients over age 60 comprise the majority of those diagnosed with AML, with a median age of a patient diagnosed with AML of about 67 years. Treatment approaches in this population are limited because a majority of these individuals are judged too frail and unable to tolerate standard induction chemotherapy or having forms of disease generally unresponsive to currently available drugs. Elderly, high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard chemotherapy, though only about a third of them do receive treatment because of toxicity. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and Weisdorf (Haematologica 2012; 1916-24).

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Dr. Turck to Provide Strategic Advice to Actinium to Support Accelerated Development and Commercialization of Iomab-B

New York, NY -- (SBWIRE) -- 02/05/2015 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors. Prior to founding TurckBio, Dr. Turck led Bayer Healthcare's Global Specialty Medicine unit, where most relevant to Actinium, he played a leadership role in the commercialization of the alpha-radiopharmaceutical Xofigo® whose successful launch he prepared in close collaboration with Algeta ASA.

Dr. Turck is a Medical Doctor with more than 20 years' pharmaceutical industry experience at Bayer, Berlex and Schering. He brings extensive oncology experience having supported in various roles the development, global launch and commercialization of several leading oncology drugs including Xofigo®, Stivarga®, Nexavar® and Campath. Throughout his career, he gained broad experience in clinical development, regulatory, market access and commercialization of oncology drugs including radiopharmaceuticals such as Xofigo® which was the most commercially successful launch of a radiopharmaceutical product to date. At TurckBio, he has worked as an independent consultant for a number of leading private and public biotechnology and pharmaceutical companies. Dr. Turck will focus his initial efforts on optimizing the commercial potential of Iomab-B.

Dr. Turck commented, "I am delighted to work with Actinium. I believe Iomab-B could shift the paradigm in how AML patients are prepared for bone marrow transplant. I am extremely impressed with the Iomab-B Phase 1/2 clinical data which I believe demonstrates Iomab-B has the potential to become a very important treatment for older relapsed and refractory AML patients most of whom have no option to receive a potentially curative bone marrow transplant. Iomab-B has the potential to prolong overall survival and improve quality of life in patients with advanced disease. I am equally excited about the significant potential of Actinium's Alpha Particle Immunotherapy Platform for which Xofigo®'s success bodes well. "

"Dr. Turck's track record of development and commercialization of several major oncology products on a global scale will be invaluable to Actinium as we move Iomab-B into its pivotal Phase 3 trial, and upon FDA approval, to commercialize the drug to meet the significant unmet need for elderly relapsed/refractory AML patients who cannot get a bone marrow transplant today." stated Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals, Inc. "The company will continue to strengthen its capabilities and leadership to support its mission to develop and commercialize lifesaving therapies to treat unmet medical needs in oncology."

About Bone Marrow Transplant
Bone marrow transplants (BMT) are most commonly used to treat leukemia and lymphoma, conditions incurred when a blood or immune cell, respectively, becomes cancerous and proliferates. Together, these diseases account for some 50,000 to 75,000 new cases annually in the United States. BMT involves first clearing a patient's body of his or her own immune cells and then transplanting bone marrow, the source of all blood- and immune-forming cells, from a tissue-matched donor. The new cells, which are free of cancer, repopulate the patient's bone marrow and eventually give rise to a functioning set of blood and immune cells, providing a lifelong cure. BMT offers the chance of a "curative" outcome (2+ year survival), and therefore can play a central role in the treatment of AML. The impact of BMT on AML continues to increase with AML being the most common and fastest growing indication for allogeneic BMT, comprising 25% to 30% of all BMT recipients. There are currently over 100,000 BMT survivors across all indications and this number is expected to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them over age 60.

About Iomab-B
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in such statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Manufacturing and Quality Control of Clinical and Commercial Quantities of Company’s Lead Drug to be Discussed with Regulatory Authorities

New York, NY -- (SBWIRE) -- 01/21/2015 -- Actinium Pharmaceuticals, Inc, a New York City-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a CMC (Chemistry, Manufacturing and Control) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing preparations for starting the pivotal Phase 3 trial by the middle of 2015. The Company expects to obtain further guidance from the FDA that will allow completion of the processes and methods for large scale manufacturing and testing of clinical and commercial grade drug product.

"We are now in the final stages in our preparations to commence the Phase 3 trial for Iomab-B while simultaneously establishing the necessary infrastructure to enable the Company to quickly commercialize Iomab-B, if approved by FDA," said Kaushik J. Dave, President and Chief Executive Officer of Actinium Pharmaceuticals, Inc. "We believe input from the FDA will be invaluable as we finalize our proprietary manufacturing processes to support both the clinical trials and future commercialization."

About AML
Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. It is characterized by an uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates there will be approximately 18,860 new cases of AML and approximately 10,460 deaths from AML in the U.S. in 2014. Patients over age 60 comprise the majority of those diagnosed with AML, with a median age at diagnosis of about 67 years. Treatment approaches in this population are limited because a majority of these individuals are judged too frail and unable to tolerate standard induction chemotherapy or as having disease generally unresponsive to currently available drugs. Elderly, high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard chemotherapy, which only about a third of them do because of toxicity. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and Weisdorf (Haematologica 2012; 1916-24.

About Iomab-B
Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in such statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Orphan-Drug Designation Anticipated to Provide Faster Regulatory Review and Financial Incentives

New York, NY -- (SBWIRE) -- 12/03/2014 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial.

On November 6, 2014, Actinium announced positive interim data from the ongoing Phase 1/2 trial of Actimab-A in older patients with newly diagnosed Acute Myeloid Leukemia ("AML"). Most notably, median overall survival ("OS") of the seven secondary AML patients (with prior myelodysplastic syndrome, or MDS) in the study was 9.1 months, which compares favorably to historical norms of 2 to 5 months depending on the treatment modality. Older AML patients are already higher risk, with secondary AML patients considered to have the more severe and less treatable form of AML, and as a consequence have shorter expected survival. The clinical abstract was published and is available online in Blood, the official Journal of the American Society of Hematology. Actinium expects additional data to be available from this trial in 2015.

Kaushik J. Dave, Ph.D., President and CEO of Actinium, stated, "The FDA's decision to grant orphan-drug status for Actimab-A is a significant milestone for the Company and recognizes the need for innovative new approaches to treat AML. The designation will provide Actinium access to various development benefits and financial incentives from the Agency, including an exemption from prescription drug user fees for Actimab-A for this indication and, if the drug receives marketing approval, it will enjoy seven years of market exclusivity in the United States."

About Orphan Drug Status
The FDA, through its Office of Orphan Products Development (OOPD), grants orphan status to drugs and biologic products that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Orphan drug designation provides a drug developer with certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication; potential tax credits on U.S. clinical trials; eligibility for orphan drug grants; and waiver of certain administrative fees.

About AML
Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. It is characterized by an uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates there will be approximately 18,860 new cases of AML and approximately 10,460 deaths from AML in the U.S. in 2014, a majority of which will be in adults. Patients over age 60 comprise the majority of those diagnosed with AML, with a median age of a patient diagnosed with AML of about 67 years. Treatment approaches in this population are limited because a majority of these individuals are judged too frail and unable to tolerate standard induction chemotherapy or having forms of disease generally unresponsive to currently available drugs. Elderly, high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard chemotherapy, though only about a third of them do receive treatment because of toxicity. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and Weisdorf (Haematologica 2012; 1916-24).

About Actimab-A
Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from leading experts at the prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Medicine, Columbia University Medical Center, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects additional updates to its Phase 1/2 clinical trial in December 2014. Actimab candidates are in early development for other cancers.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in such statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

• Significant Reductions in Bone Marrow Blasts Demonstrated • No Early Mortality Observed • ASH Abstract Highlights Actimab-A’s Significant Survival Benefit in Patients with Secondary Acute Myeloid Leukemia

New York, NY -- (SBWIRE) -- 11/10/2014 -- Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced positive interim data from the ongoing Phase I/II trial of Actimab-A in older patients with newly diagnosed Acute Myeloid Leukemia ("AML"). Most notably, median overall survival ("OS") of the seven secondary AML patients (with prior myelodysplastic syndrome, or MDS) in the study was 9.1 months, which is a prolongation of life compared to historical norms of typically 2 to 5 months.1 Older AML patients are already higher risk, with secondary AML patients considered to have the more severe and less treatable form of AML, and the shortest expected survival. The clinical abstract will be published and available online in Blood, the official Journal of the American Society of Hematology.

"Alpha emitting isotopes may result in more efficient leukemia cell killing without the toxicity of intensive chemotherapy," said Joseph Jurcic, M.D., Professor of Medicine and Director of the Hematologic Malignancies Section of the Hematology/Oncology Division at Columbia University Medical Center, and lead study investigator. "In this study, Actimab-A was safely and effectively combined with low-dose chemotherapy in older AML patients. Even at this early stage in development, the tolerability of the regimen and promising survival data in this poor-risk population are highly encouraging and support our center's commitment to this program. Because many of these patients cannot tolerate intensive chemotherapy, potentially less toxic treatments such as this are desperately needed."

"We believe the data presented provide further evidence that Actimab-A has substantial clinical activity, including a survival benefit, in the hardest to treat AML patients," said Dragan Cicic MD, Chief Medical Officer of Actinium. "The potential efficacy in killing other treatment resistant leukemia cells combined with the limited side effects identified in the study to date could offer a new hope to patients whose age, comorbidities and nature of disease currently leaves them with very limited treatment options. We continue to work with a world-class team of clinical investigators to advance this program and technology."

The interim analysis from this company-sponsored trial is consistent with results from the prior three trials in Actinium's HuM195-Alpha Program. The abstract, Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML), will be published and available online in Blood, the official Journal of the American Society of Hematology.

In this interim analysis, a total of 9 patients were evaluated thus far with a median age of 76 (range 73-81). All had intermediate or poor risk cytogenetics, and 7 of 9 patients had secondary AML as a result of prior MDS. These 7 secondary AML patients had a median OS of 9.1 months from study entry (range 2.3-24 months). Of these, 2 patients lived longer than 12 months and the longest surviving patient lived greater than 24 months. Overall, for all 9 patients median OS was 5.4 months (range 2.2-24 months.

Two dosing levels have been evaluated to date (0.5 or 1.0 ?Ci/kg/fraction), and the study is ongoing at higher doses until the maximum tolerated dose ("MTD") is reached. Despite not having yet reached MTD, the Company has observed significant bone marrow blast reductions, another important marker of efficacy. Of the 7 evaluable patients in the overall study, 5 patients (71%) had bone marrow blast reductions with a mean of 61% reduction.

The sites participating in this multi-center trial are Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Medicine, Columbia University Medical Center, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects to announce further information related to Actimab-A development subsequent to its Clinical Advisory Board meeting, during the ASH 2014 time frame (December 6-9, 2014.

Elderly, high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard chemotherapy, though only about a third of them do receive treatment because of toxicity. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and Weisdorf (Haematologica 2012; 1916-24). The majority (5 of 7) of the secondary AML patients receiving Actimab-A had been previously treated with hypomethylating agents, a criterion which would have excluded such patients from some other clinical trials. Previous treatment with hypomethylating agents, and subsequent failure, further demonstrates the disease severity of patients in the Actimab-A trial.

The safety profile of Actimab-A was satisfactory and acceptable for this patient population in this interim analysis. The only drug-related serious adverse events seen were related to myelosuppression, which is expected in the treatment of leukemia.

The antibody portion of Actimab-A, HuM195 (also known as lintuzumab) when labeled with alpha particles has been evaluated in three prior studies, including two studies of Bismab-A, which was an earlier, first generation construct, and an investigator sponsored trial with Actimab-A. Today's interim results mark the first look at what the Company believes are clinically meaningful data in the ongoing, Company sponsored Phase I/II trial of Actimab-A.

Secondary AML is a common form of AML in the U.S., and is defined as AML that develops following exposure to cytotoxic agents or as a subsequent event in another hematologic disorder, usually MDS. According to the American Cancer Society there is an annual incidence of 12,000 new cases of MDS in the U.S. Between 30% and 50% of these new cases go on to develop AML, or approximately 3,600-6,000 secondary AML patients in the U.S.

About Actimab-A
Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase I/II clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from leading experts at the prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Medicine, Columbia University Medical Center, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects additional updates to its Phase I/II clinical trial in December 2014. Actimab candidates are in early development for other cancers.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Focus of Collaboration is to develop an Antibody Actinium 225 Construct Using Novel Labeling Technology to Enable Platform Expansion

New York, NY -- (ReleaseWire) -- 10/29/2014 -- Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, and Albert Einstein College of Medicine of Yeshiva University, a research-intensive medical school in Bronx, NY, started development of an antibody construct labeled with actinium 225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform, and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies.

In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers, and in residual disease in solid cancers post-surgery.

"Adding even more possibilities to our already versatile platform further expands the reach of our technology," said Kaushik Dave, Actinium's President and CEO. "As we move ahead, we expect to be able to focus on more antigens, including those that have been considered too difficult to target until now."

Pending successful results of the preclinical work at Einstein, collaborating parties intend to continue development in clinical trials.

About Actinium 225
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Baylor Sammons Cancer Center Is One Of The Largest Oncology Centers In The Nation Treating Over 55,000 Cancer Patients Every Year

New York, NY -- (SBWIRE) -- 07/31/2014 -- Actinium Pharmaceuticals, Inc.,a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML).

M. Yair Levy, MD, Medical Director of Hematologic Malignancy Clinical Research, Baylor Research Institute, stated, "AML in the elderly is a disease that is difficult to treat with few therapeutic options. Through our participation, Baylor is pleased to be able to provide patients with the ability to enroll in the Actimab-A Phase I/II clinical trial and gain access to this innovative, targeted, low intensity therapy which is being evaluated to address this deadly disease."

Kaushik J. Dave, Ph.D., President and CEO of the Company stated, "We are pleased to work with Baylor Charles A. Sammons Cancer Center, which is one of the largest oncology centers in the nation treating over 55,000 cancer patients every year. The selection reflects its commitment and significant experience in conducting clinical trials to evaluate the newest strategies for cancer prevention, diagnosis and treatment."

The current Actimab-A clinical trial is titled "A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia" (ClinicalTrials.gov identifier NCT01756677). The Company expects to provide interim results around the same time as the American Society of Hematology (ASH) meeting in December 2014.

About Actimab-A
Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase I/II clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from leading experts at the prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center and now the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects interim Phase I/II clinical trial results in December 2014. Actimab candidates are in early development for other cancers.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies

New York, NY -- (SBWIRE) -- 07/17/2014 -- Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225.

The antibody has the potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Assuming success of this program, Actinium will select the appropriate indication for clinical development of the new construct.

"We continue to work with leading institutions including Memorial Sloan Kettering to leverage the broad utility of our alpha particle immunotherapy platform, a highly potent and selective form of targeted radiotherapy, to address significant unmet patient need in various cancer types", commented Dr. Kaushik J. Dave, President and CEO of Actinium Pharmaceuticals. "Clinical trials of drug candidates based on alpha emitting isotopes have demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. If successful, we believe this approach will further expand the field of use of alpha emitters."

Arming a versatile antibody with actinium-225 will allow further customization of treatment in various blood cancer indications and its use in expanded clinical settings due to very low levels of radiation exposure to medical personnel, other caregivers and environment. Pending successful results of the preclinical work, development will continue in clinical trials.

Alpha emitters deposit higher energy over a much shorter distance compared with beta emitters, providing single-cell kill while sparing normal surrounding tissue. Increased cell-specific potency may provide less off-target toxicity, resulting in an approach that decreases relapse rates and is better tolerated by patients. Alpha emitters may prove particularly useful for minimal-residual disease or extramedullary disease (located outside of the bone marrow), as well as in the non- hematopoietic stem cell transplantation (HSCT) setting, if conjugated/connected to select target antigens.

About Actinium 225
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alphaparticle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

M. Yair Levy, MD to Guide and Participate in Upcoming Pivotal Trial of Actinium’s Iomab™-B For Older Relapsed/Refractory Acute Myeloid Leukemia Patients

New York, NY -- (SBWIRE) -- 07/09/2014 -- Actinium Pharmaceuticals, Inc.,("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab™-B. Iomab™-B, the Company's lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications.

Dr. Levy is Medical Director, Hematologic Malignancy Clinical Research of the Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He was previously on the Faculty at Sidney Kimmel Comprehensive Care Center at Johns Hopkins, after completing a Hematology Fellowship there. Dr. Levy is Board Certified in Medical Oncology and Internal Medicine. He is also a Clinical Assistant Professor of Internal Medicine at the Texas A&M College of Medicine.

Kaushik J. Dave, Ph.D., President and CEO of the Company stated, "We are gratified to add Dr. Levy to our newly formed SAB, which includes experts in the field of oncology, hematology, and bone marrow transplant. Texas Oncology is one of the largest oncology practices in the nation treating over 55,000 cancer patients every year, and Dr. Levy's affiliation brings valuable perspective to the transplant physicians on our SAB as he is an experienced clinical trial researcher. The Texas Oncology-Baylor Charles A. Sammons Cancer Center is one of the ten largest bone marrow transplant centers in the United States."

The Company's SAB members will guide the continuing clinical development of Iomab™-B, as Principal Investigators, Advisors and Clinicians. The upcoming Iomab™-B Pivotal Clinical Trial has been planned with direct FDA input to be a randomized, controlled, multi-center, 150-patient trial evaluating the impact of Iomab-B's impact on AML as determined by a primary endpoint of durable complete remission at 6 months and a secondary endpoint of overall survival at one year.

About Iomab™-B
Iomab™-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission will include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab™-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab™-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab™-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm